Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | GLPG5101 |
Trade Name | |
Synonyms | GLPG-5101|GLPG 5101 |
Drug Descriptions |
GLPG5101 comprises T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19 and TNFRSF9 (4-1BB), which potentially induces antitumor activity (Blood (2023) 142 (Supplement 1): 2113). |
DrugClasses | CD19 Immune Cell Therapy 62 |
CAS Registry Number | NA |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
GLPG5101 | GLPG5101 | 0 | 1 |